Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.
Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.
Int J Pharm. 2020 Jul 30;585:119425. doi: 10.1016/j.ijpharm.2020.119425. Epub 2020 May 28.
Oral drug delivery systems for time-controlled release, intended for chronotherapy or colon targeting, are often in the form of coated dosage forms provided with swellable/soluble hydrophilic polymer coatings. These are responsible for programmable lag phases prior to release, due to their progressive hydration in the biological fluids. When based on high-viscosity polymers and/or manufactured by press-coating, the performance of functional hydroxypropyl methylcellulose (HPMC) layers was not fully satisfactory. Particularly, it encompassed an initial phase of slow release because of outward diffusion of the drug through a persistent gel barrier surrounding the core. To promote erosion of such a barrier, the use of a cellulolytic product (Sternzym® C13030) was here explored. For this purpose, the mass loss behavior of tableted matrices based on various HPMC grades, containing increasing percentages of Sternzym® C13030, was preliminarily studied, highlighting a clear and concentration-dependent effect of the enzyme especially with high-viscosity polymers. Subsequently, Sternzym® C13030-containing systems, wherein the cellulolytic product was either incorporated into a high-viscosity HPMC coating or formed a separate underlying layer, were manufactured. Evaluated for release, such systems gave rise to more reproducible profiles, with shortened lag phases and reduced diffusional release, as compared to the reference formulation devoid of enzyme.
用于时控释放的口服药物递送系统,旨在进行时间治疗或结肠靶向,通常采用具有可溶胀/水溶性亲水性聚合物涂层的包衣剂型。这些系统由于其在生物流体中的逐渐水合作用,负责可编程的滞后阶段,在释放之前。当基于高粘度聚合物和/或通过压制涂层制造时,功能性羟丙基甲基纤维素(HPMC)层的性能并不完全令人满意。特别是,由于药物通过围绕核心的持续凝胶屏障向外扩散,会出现初始缓慢释放阶段。为了促进这种屏障的侵蚀,本文探索了使用纤维素酶产品(Sternzym® C13030)。为此,初步研究了基于各种 HPMC 等级的片剂基质的质量损失行为,其中包含越来越多的 Sternzym® C13030,突出了酶的明显且浓度依赖性效应,特别是对于高粘度聚合物。随后,制造了含有 Sternzym® C13030 的系统,其中纤维素酶产品要么被掺入高粘度 HPMC 涂层中,要么形成单独的底层。与不含酶的参考配方相比,评估释放结果表明,这些系统产生了更可重复的曲线,滞后阶段缩短,扩散释放减少。